门冬氨酸钾镁口服液联合氟桂利嗪胶囊预防性治疗偏头痛效果观察

Clinical observation on potassium magnesium aspartate oral solution combined with flunarizine capsules for migraine prophylaxis

目的评价门冬氨酸钾镁口服液联合氟桂利嗪胶囊预防性治疗偏头痛的效果。方法选择2010年11月—2012年8月收治的偏头痛患者90例,随机分为观察组和对照组各45例,观察组在患者偏头痛缓解期内餐后口服门冬氨酸钾镁口服液10 ml/次,3次/d;睡前口服氟桂利嗪胶囊5 mg。对照组仅睡前口服氟桂利嗪胶囊5 mg。均治疗12周,比较两组头痛视觉模拟评分(visual analogue scale,VAS)和发作频率。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果 VAS、发作频率观察组治疗前分别为(6.96±1.09)分、(3.83±1.28)次/月,治疗后分别为(2.72±1.33)分、(1.92±0.59)次/月;对照组治疗前分别为(6.86±1.01)分、(3.36±1.56)次/月,治疗后分别为(3.96±1.18)分、(2.26±0.92)次/月。两组治疗前后VAS、发作频率组内比较差异均有统计学意义(均P<0.05),治疗后VAS、发作频率组间比较差异均有统计学意义(均P<0.05)。有效率观察组64.4%,对照组42.2%,两组比较差异有统计学意义(P<0.05)。不良反应发生率观察组6.67%,对照组4.44%,两组比较差异无统计学意义(P>0.05)。结论门冬氨酸钾镁口服液联合氟桂利嗪胶囊预防性治疗偏头痛有明显的协同作用,优于单用氟桂利嗪胶囊治疗。

Objective To evaluate the clinical efficacy of potassium magnesium aspartate oral solution combined with flunarizine capsules for migraine prophylaxis,Methods Ninety treated cases of migraine from November 2010 to August 2012 were randomly divided into two groups： observation group and control group,45 cases for each.Potassium magnesium aspartate oral solution was given to observation group during the remission period in a dose of 10 ml,three times a day,as well as flunarizine capsules 5 mg at bedtime.Flunarizine capsules alone was given to control group in a dose of 5 mg at bedtime.Both groups received a 12-week treatment and were compared for the visual analogue scale（VAS） and frequency of headaches afterwards.was used to represent measurement data.T-test was used for processing measurement data and χ2 test for count data,P〈0.05 indicated that the difference was statistically significant.Results In observation group,VAS and headache frequency were （6.96 ± 1.09）points and （3.83 ± 1,28）times per month respectively before treatment,and （2.72 ± 1,33）points and （1.92 ± 0.59）times per month after treatment.ln control group,VAS and headache frequency were （6.86 ± 1.01）points and （3.36 ± 1.56）times per month respectively before treatment,and （3.96 ± 1.18）points and （2.26 ± 0.92）times per monti citer treatment.Significant difference was found in VAS and h eadache frequency before and after treatment in each group（both P〈0.05）.Significant difference was found between the two groups in VAS and headache frequency after treatment（both P〈0.05）.Tbe effective rate was 64.4% in observation group and 42.2% in control group.There was significant difference between two groups.6.67% in observation group developed adverse reactions and 4.44% in control group,and there was no significant difference between two groups（P〉0.05）.Conclusion Potassium magnesium aspartate oral solution combined with flunarizine capsules shows an obvious synergetic action for migraine prophylaxis,and is superior to single use of flunarizine capsules.